AstraZeneca PLC (AZN)vsUniversal Health Services Inc (UHS)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
UHS
Universal Health Services Inc
$174.83
+1.22%
HEALTHCARE · Cap: $10.13B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 239% more annual revenue ($61.37B vs $18.11B). AZN leads profitability with a 17.0% profit margin vs 8.4%. UHS appears more attractively valued with a PEG of 1.14. UHS earns a higher WallStSmart Score of 72/100 (B).
AZN
Buy60
out of 100
Grade: C+
UHS
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-24.0%
Fair Value
$186.49
Current Price
$174.83
$11.66 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 20 in profit
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : UHS
The strongest argument for UHS centers on P/E Ratio, Price/Book, Return on Equity. PEG of 1.14 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : UHS
No major red flags identified for UHS, but monitor valuation.
Key Dynamics to Monitor
AZN profiles as a mature stock while UHS is a value play — different risk/reward profiles.
UHS carries more volatility with a beta of 1.06 — expect wider price swings.
UHS is growing revenue faster at 8.3% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
UHS scores higher overall (72/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Universal Health Services Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?